- Home
- KTTA vs CYBR Comparison
KTTA vs CYBR Comparison
Compare KTTA & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- CYBR
- Stock Information
- Founded
- KTTA 2020
- CYBR 1999
- Country
- KTTA United States
- CYBR Israel
- Employees
- KTTA N/A
- CYBR N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- CYBR Computer Software: Prepackaged Software
- Sector
- KTTA Health Care
- CYBR Technology
- Exchange
- KTTA Nasdaq
- CYBR Nasdaq
- Market Cap
- KTTA 2.8M
- CYBR 19.7B
- IPO Year
- KTTA 2021
- CYBR 2014
- Fundamental
- Price
- KTTA $0.75
- CYBR $387.92
- Analyst Decision
- KTTA
- CYBR Strong Buy
- Analyst Count
- KTTA 0
- CYBR 32
- Target Price
- KTTA N/A
- CYBR $411.56
- AVG Volume (30 Days)
- KTTA 168.4K
- CYBR 679.5K
- Earning Date
- KTTA 08-12-2025
- CYBR 08-07-2025
- Dividend Yield
- KTTA N/A
- CYBR N/A
- EPS Growth
- KTTA N/A
- CYBR N/A
- EPS
- KTTA N/A
- CYBR N/A
- Revenue
- KTTA N/A
- CYBR $1,096,793,000.00
- Revenue This Year
- KTTA N/A
- CYBR $34.80
- Revenue Next Year
- KTTA N/A
- CYBR $19.50
- P/E Ratio
- KTTA N/A
- CYBR N/A
- Revenue Growth
- KTTA N/A
- CYBR 35.12
- 52 Week Low
- KTTA $0.70
- CYBR $230.00
- 52 Week High
- KTTA $7.50
- CYBR $421.00
- Technical
- Relative Strength Index (RSI)
- KTTA 38.00
- CYBR 49.65
- Support Level
- KTTA $0.70
- CYBR $380.00
- Resistance Level
- KTTA $0.76
- CYBR $409.35
- Average True Range (ATR)
- KTTA 0.04
- CYBR 12.98
- MACD
- KTTA 0.01
- CYBR -1.57
- Stochastic Oscillator
- KTTA 27.26
- CYBR 32.15
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.